The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the ...